ARTICLE | Clinical News
IMC-1C11: Phase I testing update
December 20, 1999 8:00 AM UTC
ImClone Systems Inc. (IMCL), New York, N.Y. Product: IMC-1C11 Business: Cancer Therapeutic category: Angiogenesis, Receptor antagonist Target: KDR/VEGFr on vascular endothelial cells Description: Chim...